Treatment Information

Back

Melanoma treatment details. Immunotherapy.

Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:City/State/Province:Milan
Treatments:ImmunotherapyHospital:Istituto Nazionale per lo Studio e la Cura dei Tumori
Drugs:Journal:Link
Date:Oct 2005

Description:

Patients: This Phase II study involved 38 pretreated metastatic melanoma patients, of which 20 received at least one or two complete cycles of treatment.

Treatment: The treatment consisted of immunotherapy (autologous, tumor-derived heat shock protein gp96-peptide complex vaccine) administered with interferon-alpha.

Toxicity: Toxicities were not graded but consisted of erythema, induration, nausea, vertigo, fatigue, vomiting, malaise, fever and pain and itching at the injection site.

Results: The median overall survival was 19.2 months (583 days) for the 20 patients who received at least one or two complete cycles of treatment.

Support: The study was supported by Antigenics, a company that markets personal cancer vaccines.

Correspondence: Giorgio Parmiani, MD



Back